iuvantium

Iuvantium was founded on the conviction that immunobiology can be decoded through systematic interrogation, and that the probe to do so is inorganic in nature. Iuvantium designs inorganic nanoparticles that act as both probe and therapeutic: first interrogating the immune system to map how physicochemical properties drive immune behaviour, then encoding the precise response needed into the material itself.

Iuvantium combines more than 40 years of frontier immunology and 20 years of functional inorganic material science, embodied by our co-founders Emeritus Prof Jon Austyn and Dr. Björn Schimmöller respectively. Together they developed a platform at the intersection of inorganic chemistry and biology. Immunology has remained largely trial and error because it has been approached almost entirely through organic chemistry and biology. Iuvantium brought the toolkit of the physical sciences to it instead, and that changes what becomes possible.

Modern medicine is good at telling the immune system what to attack. It is remarkably bad at controlling how it responds. There is no reliable way to program the quality, magnitude, or type of an immune response, which is why drug development still fails roughly 90% of the time and why diseases from autoimmune conditions to many cancers remain out of reach. If immune responses could be engineered with the precision we bring to catalysts or semiconductors, it would change what medicine can do for almost every major disease category. That is the problem we exist to solve.